Sort
10,766 grants matching “checkpoint inhibitor”
HIFU-immunotherapy in pancreatic cancer
$617,146Katherine W Ferrara · Stanford University · R01 · FY2022 · CA
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$617,119Elias Sayour · University Of Florida · R01 · FY2024 · FD
Identification of human tumor-associated antigens
$617,092Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Analyses of human T regulatory cells
$617,092Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology
$616,764Nicole Franziska Steinmetz · Case Western Reserve University · U01 · FY2017 · CA
(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis
$616,751Noula Dattu Shembade · University Of Miami School Of Medicine · R01 · FY2025 · CA
Spatially resolved, single cell biomarkers of B cell lymphoma
$616,249Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2022 · CA
A model for predicting response to PD-1 inhibitors in NSCLC
$616,200Edward B Garon · University Of California Los Angeles · R01 · FY2019 · CA
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver Cancer
$616,121James S Duncan · Yale University · R01 · FY2022 · CA
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
$615,852Yun Wu · State University Of New York At Buffalo · R01 · FY2024 · CA
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$615,811Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2023 · FD
Immune correlates of LTBI in HIV-exposed infants
$615,772Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2020 · AI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$615,425John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2017 · CA
Wee1 and HDAC inhibition in relapsed/refractory AML
$615,403Steven Grant · Virginia Commonwealth University · UH2 · FY2017 · TR
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
$615,393Mitch A Phelps · Ohio State University · R01 · FY2023 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
$615,247Mehmet Toner · Massachusetts General Hospital · R01 · FY2024 · CA
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
$615,145Javid J Moslehi · University Of California, San Francisco · R01 · FY2025 · HL
Mechanism of spontaneous and DSB-induced repair
$614,873Rodney J. Rothstein · Columbia University Health Sciences · R37 · FY2014 · GM
Credentialing a Cross-Species Platform to Investigate Cancer Therapy-Associated Cardiovascular Toxicity
$614,697Iris Z Jaffe · Tufts Medical Center · R01 · FY2021 · CA
Identification of REV-ERB inverse agonists for cancer immunotherapy
$614,469Laura A Solt · University Of Florida · R01 · FY2022 · CA
Dissecting the role of hypoxia in T cell differentiation in cancer
$614,462Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Dissecting the role of hypoxia in T cell differentiation in cancer
$614,462Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Mouse models of Kras-mutant colorectal cancer
$614,235Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2022 · CA
A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
$614,203Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2024 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$614,111Heide L Ford · University Of Colorado Denver · R01 · FY2017 · CA